

All sessions take place on the 17th floor of East Village, Northeastern University

****Preliminary Schedule subject to change****

PROGRAM SCHEDULE

Thursday, July 30th, 2026

Morning Sessions

7:30am - 8:50am	<i>Continental Breakfast</i>
8:50am - 9:00am	<i>Welcome Remarks: Alexandros Makriyannis</i>
9:00am -	<i>Session 1: Presider Tom Prisinzano</i>
9:00am - 9:20am	John Traynor University of Michigan Delta Opioid Receptor Modulators as Non-Addictive Medications
9:20am - 9:40am	Jose Moron-Concepcion Washington University Pain Center Engineering Intranasal Kappa Opioid Receptor Antagonist Nanotherapeutics to Prevent Pain-Induced Negative Affect and Opioid Escalation
9:40am - 10:00am	Yan Zhang Virginia Commonwealth University Agonists or Antagonists, That is the Question
10:00am - 10:20am	Nurulain Zaveri Astraea Therapeutics The Journey from Idea to IND: A Tale of Drug Development at Two 'First-in-class' Molecular Targets for SUD
10:20am - 10:30am	Matthew C. Broomer National Institute on Drug Abuse -IRP Nucleus Accumbens Representation of Heroin and Methamphetamine Self-Administration
10:30am - 11:00am	<i>Coffee Break</i>
11:00am - 11:10am	<i>Session 2: Welcome, Carmen Sceppa, Dean Bouve College Presider:</i>
11:10am - 11:40am	Bryan Roth UNC School of Medicine. Endogenous Neuronal Signaling Complexes and Psychedelic Drug Actions
11:40am - 12:00pm	Daniel Wacker Icahn School of Medicine at Mount Sinai Structural Pharmacology of Psychedelics – Beyond the 5-HT _{2A} Receptor
12:00pm - 12:20pm	Charles Nichols LSU Health Sciences Center The role of N343 in activation and functional selectivity of 5- HT _{2A} receptors
12:20pm - 12:40pm	Brian D. Kangas McLean Hospital, Harvard Medical School Preclinical Studies Examining the Prohedonic Effects of Psychedelics
12:40pm - 2:00pm	<i>Lunch</i>

PROGRAM SCHEDULE

Thursday, July 30th, 2026

Afternoon Sessions

2:00pm -	<i>Session 3: President: Amy Newman</i>
2:00pm - 2:20pm	Alessandro Bonifazi University of Texas Medical Branch Structure-Based Design of Selective Bitopic Agonists for the Dopamine D3 Receptor
2:20 pm - 2:40pm	Oscar Solis NIDA-IRP The Role of Synaptic Zn ²⁺ in Dopaminergic Signaling and Cocaine-Induced Neuroadaptations
2:40 pm - 3:00pm	Christy Fowler University of California Irvine Targeting the Serotonin System with an AI-Derived Polypharmacy Strategy for Fentanyl Use Disorder.
3:00pm 3:20pm	Andrea Hohmann Indiana University Bloomington Harnessing the Therapeutic Potential of CB1 Allosteric Modulation
3:20pm 3:30pm	Amy Stringer Center for Substance Abuse Research, Temple University Psilocybin Reduces Opioid Seeking Behavior and Modulates Both mRNA and Cytokine Expression in the Prefrontal Cortex in a Pre-Clinical Model of Fentanyl Self-Administration
3:30pm - 4:00pm	<i>Coffee Break</i>
4:00pm-	<i>Session 4:Preside, Nurulain Zaveri</i>
4:00pm - 4:20pm	Paul W Czoty Wake Forest University Effects of “Bifunctional” Mu Opioid Peptide, Nociceptin/Orphanin FQ Peptide (NOP) Receptor Agonists in Nonhuman Primate Models of Substance Use Disorders
4:20pm - 4:40pm	Zoe Anastasia McElligott Bowles Center for Alcohol Studies UNC-Chapel Hill Biased Modulation of NTSR1 on Alcohol and Feeding Behavior
4:40pm - 5:00pm	Elizabeth A Heller University of Pennsylvania Preclinical Evidence of Nr4a1 as a Novel Therapeutic Target in Cocaine Use Disorder.